Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis
References (19)
- et al.
Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay
Trans R Soc Trop Med Hyg
(1981) Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness
Trans R Soc Trop Med Hyg
(1982)Clinical studies in human strongyloidiasis. I. Semeiology
Gastroenterology
(1950)- et al.
Detection of antibodies in strongyloidiasis by enzyme-linked immunosorbent assay (ELISA)
Trans R Soc Trop Med Hyg
(1985) - et al.
A new method to detect Strongyloides stervoralis from human stool
J Trop Med
(1988) The indirect fluorescent antibody test for the serodiagnosis of strongyloidiasis
J Trop Med Hyg
(1972)- et al.
Cutaneous larva migrans in Northern Kordofan, Sudan: a preliminary report
J Trop Med Hyg
(1977) Drug Treatment in Intestinal Helminthiases
(1973)- et al.
Antibodies to Strongyloides stercoralis larval surface antigens in chronic strongyloidiasis
Lab Invest
(1983)
Cited by (51)
Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial
2019, The Lancet Infectious DiseasesCitation Excerpt :Although cross-reactivity with other helminth infections is possible, serological specificity is close to 100% when antibody concentrations are above defined cutoff values.10 Serology is also suitable for post-treatment monitoring, and criteria to define response to treatment with this method have been assessed by diagnostic studies.11–13 Evidence before this study
Use of dried blood spots to define antibody response to the Strongyloides stercoralis recombinant antigen NIE
2014, Acta TropicaCitation Excerpt :Several other studies show a consistent decrease in Strongyloides antibody titre following treatment with follow up periods ranging from 6 to 24 months (Biggs et al., 2009; Karunajeewa et al., 2006; Kobayashi et al., 1994; Loutfy et al., 2002). A serologic follow up period of 6–12 months has been proposed as a reasonable evaluation of treatment efficacy (Loutfy et al., 2002; Requena-Méndez et al., 2013), although serorevision may take longer among patients with very high starting titres (Kobayashi et al., 1994). Of note however, most of these serologic follow up studies have been undertaken in non-endemic settings, where the risk of re-infection is minimal.
Prevention of strongyloides hyperinfection syndrome: A rheumatological point of view
2009, European Journal of Internal MedicineSecondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases
2009, International Journal of Infectious DiseasesCitation Excerpt :A potentially promising method for determining response to treatment is following sequential serology, most commonly the ELISA. Antibody titers decrease after therapy, and the ratio of pre- and post-treatment antibody levels, using a cut-off of <0.6, can be used to document response.14 Although this method has been useful to determine response to therapy in some studies,15,16 it is unclear if serology can determine complete eradication of strongyloides.
Strongyloides stercoralis hyperinfection presenting as acute respiratory failure and Gram-negative sepsis in a patient with astrocytoma
2009, International Journal of Infectious DiseasesCitation Excerpt :In one case of refractory disseminated strongyloidiasis, combined albendazole and ivermectin has been successful.20 Antistrongyloides antibody titers can also confirm the adequacy of treatment and need to be repeated after three months.21 Strongyloidiasis hyperinfection syndrome carries a high mortality approaching 100%; mortality with therapy can exceed 25%.22,23
Evidence-based clinical guidelines for immigrants and refugees
2011, CMAJ. Canadian Medical Association JournalCitation Excerpt :The National Reference Centre for Parasitology in Montréal, which performs serologic testing for both parasites in Canada, estimates that its enzyme immunoassays have 100% sensitivity and 88% specificity for Strongyloides stercoralis and 96% sensitivity and 82% specificity for Schistosoma mansoni. Several studies have reported levels of antibodies to Strongyloides declining after treatment,48,340–343 which suggests that serologic positivity is indicative of current infection; however, this has not been a universal finding.315 Levels of antibodies to Schistosoma do not appear to decline after treatment.317